treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
Published 5 years ago • 600 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
3:13
prostate cancer: treatment sequencing and choice
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
1:12
dr. pal on sequencing abiraterone and enzalutamide in mcrpc
-
4:34
card: cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
-
6:23
dr t p sahoo | cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer
-
4:17
opaganib for mcrpc after abiraterone or enzalutamide
-
3:09
mcrpc: sequencing therapy
-
0:45
treatment sequencing for metastatic castration-resistant prostate cancer
-
4:59
an overview of sequencing in mcrpc
-
2:39
prospects and progress of treatments for mcrpc
-
1:22
cabazitaxel improves rpfs in patients with mcrpc
-
2:56
therap: lupsma versus cabazitaxel for prostate cancer
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
2:07
chaarted2: cabazitaxel plus abiraterone vs. abiraterone alone for metastatic crpc
-
2:06
mcrpc: cabazitaxel re-challenge
-
8:12
the use of abiraterone and enzalutamide against crpc
-
3:47
cabazitaxel safe and effective in mcrpc
-
2:04
a phase ii trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer
-
1:55
dr. sweeney on chemotherapy versus abiraterone for mcrpc